{"id":7207,"date":"2019-05-23T17:28:19","date_gmt":"2019-05-24T00:28:19","guid":{"rendered":"https:\/\/www.bluerocktx.com\/?p=7207"},"modified":"2023-06-26T14:33:42","modified_gmt":"2023-06-26T18:33:42","slug":"bluerock-therapeutics-to-participate-at-upcoming-conferences-2","status":"publish","type":"post","link":"https:\/\/www.bluerocktx.com\/bluerock-therapeutics-to-participate-at-upcoming-conferences-2\/","title":{"rendered":"BlueRock Therapeutics to Participate at Upcoming Conferences"},"content":{"rendered":"
CAMBRIDGE, Mass., May 23, 2019 \u2013<\/strong>\u00a0BlueRock Therapeutics, LP, an engineered cell therapy company leveraging its novel\u00a0CELL+GENE™\u00a0<\/em>platform to develop regenerative medicines for intractable diseases, today announced that the company will present at the following upcoming conferences. Presentation details are as follows:<\/p>\n BIO International Convention<\/strong><\/p>\n Corporate Presentation<\/p>\n Date:\u00a0<\/strong>Tuesday, June 4, 2019<\/p>\n Time:\u00a0<\/strong>2:15 p.m. EDT<\/p>\n Location:\u00a0<\/strong>Pennsylvania Convention Center, Philadelphia, Theater 3<\/p>\n Jefferies 2019 Global Healthcare Conference<\/strong><\/p>\n Corporate Presentation<\/p>\n Date:\u00a0<\/strong>Wednesday, June 5, 2019<\/p>\n Time:\u00a0<\/strong>11:00 a.m. EDT<\/p>\n Location:\u00a0<\/strong>Grand Hyatt, New York<\/p>\n About BlueRock Therapeutics<\/strong><\/p>\n BlueRock Therapeutics is an engineered cell therapy company with a mission to develop regenerative medicines for intractable diseases. BlueRock\u2019s\u00a0CELL+GENE™<\/em>\u00a0platform harnesses the power of cells for new medicines across neurology, immunology, and cardiology. BlueRock\u2019s cell differentiation technology recapitulates the cell\u2019s developmental biology to produce native cell therapies which are further engineered for additional function. Utilizing these cell therapies to replace damaged or degenerated tissue brings the potential to restore or regenerate lost function. BlueRock was founded in 2016 by Versant Ventures and capitalized with one of the largest-ever Series A financings in biotech history by Bayer AG and Versant. BlueRock\u2019s culture is defined by scientific innovation, highest ethical standards and an urgency to bring transformative treatments to all who would benefit. For more information, visit\u00a0www.bluerocktx.com<\/span><\/a>.<\/p>\n ###<\/p>\n Investors:<\/strong><\/p>\n Candice Ellis<\/p>\n Associate Director, Investor Relations and Corporate Communications<\/p>\n (857) 777-1921<\/p>\n